WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will take part in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5th, at 10:30 AM ET.
A live webcast of the panel discussion and fireside chat at the Jefferies Global Healthcare Conference will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.
Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718
The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider,…
BEIJING, March 11, 2025 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"),…
ATLANTA and DEGGENDORF, Germany, March 11, 2025 /PRNewswire/ -- AMI®, the global leader in Dynamic…
SEOUL, South Korea and NEWPORT BEACH, Calif., March 11, 2025 /PRNewswire/ -- Medit (www.medit.com), a…
Special offers and a two-year warranty across selected premium TVs, refrigerators, air conditioners, and washing…
Recent Federal Court Ruling Denying Request for an Injunction Will Endanger Patients by Limiting Access…